Abstract: Overactive bladder (OAB) is a prevalent and costly condition that can affect any age group. Typical symptoms include urinary urgency, frequency, incontinence and nocturia. OAB occurs as a result of abnormal contractions of the bladder detrusor muscle caused by the stimulation of certain muscarinic receptors. Therefore, antimuscarinic agents have long been considered the mainstay of pharmacologic treatment for OAB. Currently, there are fi ve such agents approved for the management of OAB in the United States: oxybutynin, tolterodine, trospium, solifenacin and darifenacin. This article summarizes the effi cacy, contraindications, precautions, dosing and common side effects of these agents. All available clinical trials on trospium, solifenacin and darifenacin were reviewed to determine its place in therapy.
Introduction
Overactive bladder (OAB) is a clinical condition characterized by urinary urgency with or without incontinence, urinary frequency and nocturia (Abrams 2002; Ouslander 2004) . Patients with OAB typically present with symptoms of a sudden and compelling need to urinate which is diffi cult to defer (urgency), involuntary leakage of urine with feelings of urgency (urge urinary incontinence), frequency (Ն8 micturitions in 24 hours) and nocturia (Ն one awakening per night to void) (Herbison 2003) . In addition, patients with OAB tend to display poor health status, activity restriction, social isolation, depressive symptoms and decreased quality of life (Herbison 2003; Stewart 2003; Ouslander 2004; . OAB affects approximately 17% of the population in the United States. Although incidence increases with advanced age, OAB may affect individuals of all age groups (Stewart 2003) . In 2000, the direct and indirect expenses associated with OAB were about $12 billion. The burden of diagnosis and treatment contributed to only 0.6% ($78 million) and 23% ($2.8 billion) of the total costs, respectively (Hu 2003) .
OAB occurs as a result of abnormal and involuntary contractions of the detrusor muscle in the bladder, which is embedded by muscarinic receptors (M2 and M3 subtypes). Stimulation of M2 and M3 receptors by acetylcholine causes bladder contractions that leads to urination Erdem 2006) . Normally, the detrusor muscle remains at rest as the bladder is fi lled by urine (fi lling phase). However, it contracts during the fi lling phase in patients with OAB. Therefore, muscarinic receptor antagonists (antimuscarinic agents) are considered the mainstay of pharmacologic treatment for OAB (Erdem 2006) . contraindicated in patients with narrow-angle glaucoma, urinary retention and gastric retention. These medications should be given with caution to the elderly, particularly those with gastroesophageal refl ux (GERD), constipation, or impaired cognitive function. It is also imperative to monitor patient drug regimens for polypharmacy, potential drug interactions and other drug-related problems (Ouslander 2002 and Erdem 2006 
Oxybutynin and tolterodine
Oxybutynin is a relatively nonselective antimuscarinic agent which has been used for the management of OAB for over 30 years (Product Information 2004a; (Abramovicz et al 2001 (Abramovicz et al , 2003 .
Tolterodine is a competitive muscarinic receptor antagonist which gained FDA approval for the treatment of OAB in 1998. Two formulations are available: an IR capsule taken twice daily (Detrol ® , Pfi zer) and an ER capsule taken once daily (Detrol LA ® , Pfi zer). Oxybutynin and tolterodine have been commonly associated with adverse effects such as dry mouth, constipation, headache, dyspepsia, and dry eyes. Cognitive impairment, tachycardia and urinary retention may also occur. (Abramovicz et al 2001 (Abramovicz et al , 2003 . The ER formulations of these agents have shown to be better tolerated, particularly with respect to dry mouth, and more effective than the respective IR-formulations.
Oxybutynin and tolterodine have demonstrated their effi cacy in the management of OAB in multiple placebocontrolled studies (Abramovicz et al 2003; Product Information 2004a . Here we summarize four major trials that directly compare these two agents.
The Overactive Bladder: Judging Effective Control and Treatment (OBJECT) study was a prospective, randomized, double-blind, parallel-group study that compared the effi cacy and tolerability of oxybutynin-ER (10 mg once daily) to tolterodine-IR (2 mg twice daily). A total of 378 patients were treated with one of the agents for 12 weeks. About 88% (332 patients) completed the study. Results showed that oxybutynin-ER was signifi cantly more effective than tolterodine-IR in weekly urge incontinence (p = 0.03), total incontinence (p = 0.02) and micturition frequency episodes (p = 0.02). However, both agents signifi cantly improved symptoms of OAB from baseline as evaluated by the 3 outcomes measures (p Ͻ 0.001). Adverse events were similar among all patients, with dry mouth being reported most commonly (28.1% oxybutynin-ER group, 33.2% tolterodine-IR group) (Appell et al 2001) .
The Overactive Bladder: Performance of Extended-Release Agents (OPERA) trial was a 12-week double-blind study which randomized 790 women with OAB to receive either oxybutynin-ER 10 mg once daily or tolterodine-ER 4 mg once daily. At 12 weeks, results showed similar improvements in weekly urge urinary incontinence for both groups as well as a signifi cantly greater reduction in micturition frequency in the oxybutynin-ER group (p = 0.003). A greater percentage of women in the oxybutynin-ER group reported no episodes of urinary incontinence as compared to those in the tolterodine-ER group (23% vs 16.8%, p = 0.03). Tolerability was similar among all women, with the exception of dry mouth which was more commonly reported in the oxybutynin-ER group (p = 0.02) (Kiokno et al 2003) .
The Antimuscarinic Clinical Effectiveness Trial (ACET) consisted of two identically designed open-label trials that randomized 1,289 participants with OAB to receive tolterodine-ER 2 mg or 4 mg once daily, or oxybutynin-ER 5 mg or 10 mg once daily for 8 weeks. At the end of the trial, more patients in the tolterodine-ER groups reported an improvement in their bladder condition (60% tolterodine-ER 2 mg group, 70% tolterodine-ER 4 mg group, 59% oxybutynin-ER 5 mg group, and 60% oxybutynin-ER 10 mg group; p Ͻ 0.01 vs oxybutynin-ER 10 mg). Furthermore, the response to therapy was greater in patients whose perception of bladder symptoms were moderate to severe at the beginning of the trial. In terms of adverse effects, dose-dependent dry mouth was most commonly reported in both groups, but a lower severity was reported in the tolterodine-ER group (Sussman et al 2002) .
Another study compared the effi cacy and safety of the transdermal oxybutynin to oral tolterodine-ER and placebo in the treatment of OAB. This 12-week, double-blind study randomized 361 patients to receive twice weekly transdermal oxybutynin (3.9 mg/day), tolterodine-ER 4 mg once daily, or placebo after withdrawal of previous treatments. At the end of the study, signifi cant reductions in the number of daily incontinence episodes (median change of -3 in the transdermal oxybutynin group, and −3 in the tolterodine-ER group vs −2 in the placebo group; p Ͻ 0.05), increases in the average void volume (median change of 24 mL and 29 mL vs 5.5 mL; p Ͻ 0.01), and improved quality of life based on questionnaire answers were observed. The most commonly reported adverse effects in the transdermal oxybutynin group were application site pruritus (14% vs 4% placebo) and erythema (8.3% vs 1.7% placebo). The incidence of dry mouth in this groups was 4.1% as compared to 7.3% in the tolterodine-ER group and 1.7% in the placebo group (p Ͻ 0.05) (Dmochowski et al 2003) .
Trospium
In May 2004, trospium (Sanctura ® , Esprit/Indevus) gained FDA approval for the management of OAB (Product Information 2004c). Trospium is a quaternary ammonium compound that has antimuscarinic properties ( Figure 1 ). Trospium has high water solubility, low oral bioavailability and thus poor penetration into the central nervous system (CNS). These characteristics explain its lesser pronounced CNS side effects when compared to oxybutynin, a tertiary amine (Todorova et al 2001) . Table 1 compares its pharmacokinetics to that of other agents for the management of OAB. The recommended dose is 20 mg twice daily at least 1 hour before meals or administered on an empty stomach. The dosage should be reduced to 20 mg once daily in patients with creatinine clearance (CrCl) Ͻ30 mL/min or patients Ն75 years of age (Product Information 2004c).
The effi cacy of trospium was evaluated in two multicenter, double-blind, randomized, placebo-controlled, 12-week studies (Product Information 2004c; Zinner et al 2004; Rudy et al 2006a) . Entry criteria required that patients have urge or mixed incontinence (with a predominance of urge), urge incontinence episodes of Ն7 per week, and Ͼ70 micturitions per week. The effi cacy outcomes included improvement in urinary frequency, urge incontinence and urinary void volume. Of the 591 patients who received trospium, 249 (42%) were Ն65 years of age and 89 (15%) were Ն75 years of age (Product Information 2004c).
In one study, 262 patients received trospium 20 mg twice daily and 261 patients received placebo for 12 weeks (Table 2) (Zinner et al 2004) . The majority of patients were Caucasian (85%) and female (74%) ranging in age between 21 and 90 years. The mean change from baseline in urinary frequency was −1.3 in the patients who received placebo and −2.4 in those who received trospium (p Ͻ 0.001). The mean change from baseline in urge incontinence episodes per week was -13.9 for the placebo group and −15.4 for the trospium group (p = 0.012). The mean change from baseline in urinary void volume was +7.7 mL in patients who received placebo and +32.1 mL in those who received trospium (p Ͻ0.001). About 8.8% of those in trospium group and 5.7% of placebo group discontinued from the study due to adverse events.
In another study, a total of 329 patients received trospium 20 mg twice daily and 329 patients received placebo for 12 weeks (Table 2) (Rudy et al 2006a) . The majority of patients were Caucasian (88%) and female (82%) ranging in age between 19 and 94 years. The mean change from baseline in urinary frequency was −1.8 in the patients who received placebo and −2.7 in those who received trospium (p Ͻ 0.001). The mean change from baseline in urge incontinence episodes per week was −12.1 for the placebo group and −16.1 for the trospium group (p Ͻ 0.001). The mean change in urinary void volume was +9.4 mL in patients who received placebo and +35.6 mL in those who received trospium (p Ͻ 0.001). Effi cacy of trospium could be seen within 7 days of therapy (Rudy et al 2006b) .
Dry mouth and constipation were reported in 20% and 10% of patients in the clinical trials, respectively. Other adverse events reported were headache (4%), fatigue (2%), dyspepsia (1%), and fl atulence (1%). Drug interactions may occur when coadministing trospium with drugs that are renally eliminated by active tubular secretion (digoxin, procainamide, pancuronium, morphine, vancomycin, metformin, and tenofovir). Due to competition in renal elimination, serum concentration of trospium and/or the coadministered drug can increase (Product Information 2004c). Placebo n = 253, trospium n = 248 in Zinner et al (2004) .
Placebo n = 320, trospium n = 319 in Rudy et al (2006a) . , Yamanouchi/GlaxoSmithKline) is a muscarinic blocker for the management of OAB. It is a competitive, selective M1 and M3 receptor antagonist. In animal studies, the selectivity of solifenacin for the bladder over the salivary glands was greater than that of tolterodine, oxybutynin, darifenacin or atropine (Simpson et al 2005) . The starting dosage is 5 mg daily with or without food, and may be titrated to 10 mg daily as tolerated. A maximum daily dose of 5 mg is recommended in patients with CrCl Ͻ30 mL/min, with Child-Pugh B hepatic impairment, or receiving potent cytochrome P450 enzyme (CYP) 3A4 inhibitors, such as ketoconazole (Product Information 2004d) .
Four 12-week, double-blind, randomized, placebocontrolled, parallel group, multicenter clinical trials evaluated the effi cacy and safety of solifenacin for the management of OAB (Gittelman et al 2003; Cardozo et al 2004; Chapple et al 2004; Haab et al 2005) . All patients were required to have symptoms of OAB for Ն3 months. These studies involved 3027 patients (1811 on solifenacin and 1216 on placebo), and approximately 90% of these patients completed the studies. The majority of patients were Caucasian (93%) and female (80%) with a mean age of 58 years. At 12-weeks, the mean reduction in the number of micturitions per 24 hours was greater with solifenacin 5 mg (−2.3; p Ͻ 0.001) and solifenacin 10 mg (−2.7; p Ͻ 0.001) as compared to placebo (−1.4). The mean reduction in the number of daily incontinence episodes was greater with solifenacin 5 mg (−1.5; p Ͻ 0.001) and solifenacin 10 mg (−1.8; p Ͻ 0.001) as compared to placebo (−1.1). The mean increase in the volume voided per micturition was signifi cantly greater with solifenacin 5 mg (+32.3 mL; p Ͻ 0.001) and solifenacin 10 mg (+42.5 mL; p Ͻ 0.001) compared to placebo (+8.5 mL). Similar safety and effectiveness were observed between older (623 patients Ն65 years and 189 patients Ն75 years) and younger patients (Product Information 2004d). Table 3 reports the major results from four individual 12-week clinical trials.
Solifenacin demonstrated similar efficacy when compared to tolterodine-IR 2 mg twice daily in a randomized, double-blind, 12-week trial (Chapple et al 2004) . Compared to baseline, the mean change in number of urgency episodes per 24 hours were: −1.41 (placebo); −2.85 (solifenacin 5 mg); −3.07 (solifenacin 10 mg) and −2.05 (tolterodine-IR). The changes in episodes of incontinence were: −0.76 (placebo), −1.42 (solifenacin 5 mg), −1.45 (solifenacin 10 mg) and −1.14 (tolterodine-IR). The mean number of voids in 24 hours were: −1.20 (placebo), −2.19 (solifenacin 5 mg), −2.61 (solifenacin 10 mg), and −1.88 (tolterodine-IR). The mean volume voided per micturition was signifi cantly higher with all three active treatments (48 to 41 mL). The most common side effects reported were dry mouth (solifenacin 14%-21%, tolterodine-IR 19%), constipation (solifenacin 7%-8%, tolterodine-IR 3%) and blurred vision (solifenacin 4%-6%, tolterodine-IR 2%). In another study, solifenacin showed greater effi cacy to tolterodine-ER 4 mg once daily in decreasing urgency episodes, incontinence, and pad usage and increasing the volume voided per micturition . More patients in the solifenacin group reported improvements in perception of bladder symptoms.
The long-term effi cacy and safety of solifenacin were demonstrated in a 52-week study (12-week phase III study followed by a 40-week open-label extension study) (Haab et al 2005) . Eighty-one percent of 1637 patients completed the study with 4.7% of patients discontinuing treatment due to adverse events. Improvements in OAB symptoms were noted for all patients for up to 52 weeks of treatment. Patient satisfaction with solifenacin tolerability and effi cacy was high at 85% and 74%, respectively. Solifenacin also signifi cantly improved the quality of life in patients with OAB symptoms after 12 weeks of treatment, with further improvements during long-term administration up to 1 year (Haab et al 2005; Kelleher et al 2005) .
Common side effects reported were dry mouth (11%, 28%), constipation (5%, 13%), blurred vision (4%, 5%), and dyspepsia (1%, 4%) for solifenacin 5 mg and solifenacin 10 mg, respectively (Product Information 2004d). Patients should be advised to contact their physician if they experience severe abdominal pain or become constipated for 3 or more days. Drug Interactions must be monitored between solifenacin and potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir, nelfi navir, clarithromycin, and nefazodone).
Darifenacin
In December 2004, darifenacin (Enablex ® , Novartis), another muscarinic receptor antagonist, was approved for the management of OAB (Product Information 2004b) . It has a greater affinity for the bladder-specific M3 receptor. The recommended starting dose is 7.5 mg once daily with or without food. After two weeks of therapy, the dose may be increased to 15 mg once daily if tolerated. The maximum daily dose of 7.5 mg is recommended in patients with moderate hepatic impairment or in those taking potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin, and nefazodone) concomitantly. Darifenacin should be administered with caution to patients with severe hepatic impairment. Patients should swallow the whole tablets without chewing, crushing or dividing.
Four randomized, double-blind, placebo-controlled, multicenter, 12-week studies evaluated the effi cacy and safety (Haab et al 2004; Steers et al 2005; Hill et al 2006) . The majority of patients were white (94%) and female (84%), with a mean age of 58 years (range: 19 to 93 years). All patients had Ն8 micturitions and Ն1 episode of urinary urgency per day and Ն5 episodes of urge urinary incontinence per week for at least six months. A signifi cant decrease in weekly urge incontinence from baseline was observed in all four studies. Reductions in weekly incontinence were observed within the fi rst 2 weeks in patients treated with darifenacin. Table 4 reports the major results from four individual 12-week clinical trials (Product Information 2004b ).
An analysis of pooled data from three phase III, multicenter, double-blind, 12-week clinical trials (n = 1059 adults, 85% women) confi rmed the effi cacy and safety of darifenacin in OAB. Darifenacin reduced the number of weekly incontinence episodes by 8.8 (median) at 7.5 mg, and 10.6 (median) at 15 mg (both p Ͻ 0.01 versus placebo). Darifenacin also reduced the frequency and severity of urgency, voiding frequency, and number of signifi cant leaks, and increased bladder capacity .
Darifenacin provides comparable effi cacy with improved tolerability when compared to oxybutynin. A double-blind study randomized 76 adults with OAB to receive 2 weeks each of darifenacin 15 and 30 mg once daily, oxybutynin 5 mg three times daily and placebo, in random sequence at 10-day intervals. Darifenacin and oxybutynin signifi cantly reduced incontinence episodes, and the number/severity of urgency episodes (all Table 5 Considerations for individualizing therapy for overactive bladder (Product Information 2004a , 2004b , 2004c , 2004d (Zinner et al 2005) .
In all fi xed-dose phase III studies combined, 3.3% of patients treated with darifenacin discontinued due to adverse events versus 2.6% in placebo. Dry mouth and constipation were the leading causes of treatment discontinuation. The most common adverse effects associated with darifenacin 7.5 mg and 15 mg, respectively, were: dry mouth (20%, 35%), constipation (15%, 21%), dyspepsia (3%, 8%), urinary tract infection (5%, 5%) and abdominal pain (2%, 4%). Darifenacin is extensively metabolized by CYP2D6 and CYP3A4. Daily coadministration of darifenacin 30 mg with a potent CYP2D6 inhibitor (eg, paroxetine) can lead to a 33% increase of darifenacin drug exposure at steady state (Product Information 2004b) .
Similar to other anticholinergic drugs, all newer agents for the management of OAB (trospium, solifenacin and darifenacin) are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma (Product Information 2004b) . Use these agents cautiously in patients with clinically signifi cant bladder outfl ow obstruction, ulcerative colitis, intestinal atony, gastrointestinal obstructive disorders, myasthenia gravis, narrow-angle glaucoma, and moderate/severe hepatic dysfunction. Patients should be informed of possible anticholinergic side effects, such as heat prostration (fever and heat stroke due to decreased sweating in hot environment), dry mouth, constipation, dry eyes, urinary retention, dizziness and blurred vision. Use these agents only if the potential benefi ts outweigh the risks associated with therapy (Product Information 2004b).
Summary
Antimuscarinic agents are the mainstay of pharmacologic treatment of OAB. Currently available drugs indicated for the treatment of OAB with symptoms of urge urinary incontinence, urgency and frequency are: oxybutynin, tolterodine, trospium, solifenacin and darifenacin. All of these agents have demonstrated effi cacy and safety in placebocontrolled clinical trials. Additionally, they have similar contraindications, precautions and side effect profi les (dry mouth, constipation and other anticholinergic effects). Management of urinary symptoms associated with OAB should be individualized based on patient renal/hepatic function, medical conditions and concurrent medication use. Dosing convenience and drug cost should be considered to promote patient compliance (Table 5 ). Anticholinergic side effects should be monitor closely, especially in the elderly and those who take other anticholinergic agents concomitantly. Ideally, patient medication regimen should be reviewed periodically for therapeutic effi cacy, drug toxicity, clinical signifi cant drug interactions and other drug-related problems.
